Bipolar I Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Bipolar I Disorder Market Outlook

Thelansis’s “Bipolar I Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bipolar I Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Bipolar I Disorder Overview

Bipolar I disorder is a persistent mental health condition characterized by alternating phases of heightened mood, known as mania, and low mood, known as depression. Mania is described as a distinct period of excessively elevated, expansive, or irritable mood, accompanied by increased activity or energy, lasting at least a week and occurring most days, often requiring hospitalization if shorter. This disorder affects approximately 1 in 100 adults, posing a significant public health concern. It typically manifests with a mix of manic and depressive symptoms, leading to severe disruptions in mood lasting weeks or months, impacting various aspects of daily life and functioning. While the monoaminergic neurotransmitter systems—such as serotonin, norepinephrine, and dopamine—have been central to theories and research on mood disorder origins, no single neurotransmitter system dysfunction has been conclusively identified in bipolar disorder despite evidence suggesting their involvement. In the long-term course of bipolar I disorder, most episodes lack mood-incongruent psychotic symptoms (MIS), although the majority of patients experience them. Those with MIS tend to be male, require treatment at a younger age, rarely exhibit initial symptoms after age 50, have more relatives with schizophrenia, retire earlier due to disability, and are less likely to have stable partnerships compared to those without MIS. Lithium remains the primary treatment for managing bipolar I disorder, recognized for its efficacy in preventing suicide among bipolar patients. In June 2021, the FDA approved Lybalvi® (olanzapine/samidorphan) for various indications, including acute manic episodes or mixed features in adults with schizophrenia or bipolar I disorder.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: